A recently published case study described the administration of CAR T cells to a patient with treatment-refractory stiff-person syndrome (SPS) with anti-GAD65 (glutamic acid decarboxylase) antibodies in both CSF and serum, which specifically target GABAergic inhibitory pathways. This evidence concerns the gene GAD2 and stiff-person syndrome.